A review of strontium ranelate and its effect on DXA scans.

@article{Blake2007ARO,
  title={A review of strontium ranelate and its effect on DXA scans.},
  author={Glen Mervyn Blake and E Michael Lewiecki and David L. Kendler and Ignac Fogelman},
  journal={Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry},
  year={2007},
  volume={10 2},
  pages={113-9}
}
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures. This review article examines the evidence for the antifracture efficacy and safety of strontium ranelate treatment and discusses the effect of DXA scans, biochemical markers of bone turnover, and bone histology. In the SOTI trial, three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a new orally administered agent for the treatment of women with postmenopausal osteoporosis that reduces the risk of vertebral and nonvertebral fractures .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
Strontium ranelate is a useful addition to the range of antifracture treatments available for treating postmenopausal women with osteoporosis and is the only treatment proven to be effective at preventing both vertebral and nonvertebral fractures in women aged 80 yr and older .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
In the SOTI trial , three years treatment with strontium ranelate led to a 41% reduction in vertebral fracture risk ( relative risk [ RR]=0.59 ; 95% CI : 0.48 - 0.73 ; p<0.001 ) , while in the TROPOS study there was a 16% reduction in nonvertebral fractures ( RR=0.84 ; 95% CI 0.702 - 0.995 ; p=0.04 ) .
All Topics